26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that is used not only to monitor disease activity and response to drugs and to prognosticate disease course in people with multiple sclerosis on the group level. The absence of representative reference values to correct for physiological age-dependent increases in sNfL has limited the diagnostic use of this biomarker at an individual level. We aimed to assess the applicability of sNfL for identification of people at risk for future disease activity by establishing a reference database to derive reference values corrected for age and body-mass index (BMI). Furthermore, we used the reference database to test the suitability of sNfL as an endpoint for group-level comparison of effectiveness across disease-modifying therapies.

          Related collections

          Author and article information

          Journal
          Lancet Neurol
          The Lancet. Neurology
          Elsevier BV
          1474-4465
          1474-4422
          March 2022
          : 21
          : 3
          Affiliations
          [1 ] Department of Clinical Research, Clinical Trial Unit, University Hospital Basel, University of Basel, Basel, Switzerland.
          [2 ] Neurologic Clinic and Policlinic, MS Centre and Research Centre for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
          [3 ] Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
          [4 ] Department of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland.
          [5 ] Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
          [6 ] Department of Neurosciences, Division of Neurology, Unit of Neuroimmunology and Neuromuscular Diseases, University Hospital of Geneva and Faculty of Medicine, Geneva, Switzerland.
          [7 ] Department of Medicine, Cardiology Division, Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
          [8 ] Department of Neurology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
          [9 ] Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
          [10 ] Department of Clinical Neurosciences, Service of Neurology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
          [11 ] Department of Neurology, Bern University Hospital, University of Bern, Bern, Switzerland.
          [12 ] Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, University of Gothenburg, Mölndal, Sweden.
          [13 ] Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, University of Gothenburg, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; UK Dementia Research Institute at UCL, London, UK.
          [14 ] Department of Neurology, Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Lugano, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
          [15 ] Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
          [16 ] Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
          [17 ] Department of Health Sciences, University of Genoa, Genoa, Italy.
          [18 ] Neurologic Clinic and Policlinic, MS Centre and Research Centre for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland; Department of Medicine and Biomedical Engineering, Translational Imaging in Neurology Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
          [19 ] Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Center for Neurology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden.
          [20 ] Neurologic Clinic and Policlinic, MS Centre and Research Centre for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland. Electronic address: jens.kuhle@usb.ch.
          Article
          S1474-4422(22)00009-6
          10.1016/S1474-4422(22)00009-6
          35182510
          265616f8-9532-4b0e-9e31-f2329bd6b873
          Copyright © 2022 Elsevier Ltd. All rights reserved.
          History

          Comments

          Comment on this article